Trevi to Present CORAL Analyses and Drug–Drug Interaction Data at ATS 2026 Orlando
Trevi Therapeutics will present primary and subgroup analyses from its Phase 2b CORAL trial of nalbuphine ER in 165 IPF chronic cough patients at ATS 2026 in Orlando. The company will also share Phase 1 drug–drug interaction data with pirfenidone or nintedanib and RIVER trial efficacy in refractory cough.
1. Conference Participation
Trevi Therapeutics will deliver an oral presentation and showcase six posters at the American Thoracic Society 2026 Conference in Orlando from May 15 to 20, including session B95 on May 18 where primary and subgroup analyses from the CORAL trial will be discussed.
2. Phase 2b CORAL Trial Analyses
The Phase 2b CORAL trial randomized 165 patients with IPF-related chronic cough to nalbuphine ER doses of 27 mg, 54 mg and 108 mg twice daily or placebo over six weeks, with the primary endpoint measuring relative change in 24-hour cough frequency at Week 6.
3. Phase 1 Drug–Drug Interaction Study
A Phase 1 study will present pharmacokinetic and safety data on co-administration of nalbuphine ER with anti-fibrotic therapies pirfenidone or nintedanib, assessing potential interactions in healthy volunteer cohorts.
4. Phase 2a RIVER Trial Efficacy
Findings from the Phase 2a RIVER crossover trial will evaluate the effect of escalating nalbuphine ER doses on cough bout reductions in refractory chronic cough patients across consecutive 21-day treatment periods.